GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (FRA:4QK) » Definitions » Short Interest

Codexis (FRA:4QK) Short Interest


View and export this data going back to 2010. Start your Free Trial

What is Codexis Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Codexis's Short Interest

For the Biotechnology subindustry, Codexis's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Codexis's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codexis's Short Interest distribution charts can be found below:

* The bar in red indicates where Codexis's Short Interest falls into.


;
;

Codexis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (FRA:4QK) » Definitions » Short Interest
Comparable Companies
OCGN CRVS DSGN ABEO ITOS CKPT XOMA NVCT CDTX MNPR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
CDXS:USA 0I0X:UK 4QK:Germany
Address
200 Penobscot Drive, Redwood City, CA, USA, 94063
Website
https://www.codexis.com
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Codexis Headlines

No Headlines